Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- Matthew D. Hellmann
- , Naiyer A. Rizvi
- , Jonathan W. Goldman
- , Scott N. Gettinger
- , Hossein Borghaei
- , Julie R. Brahmer
- , Neal E. Ready
- , David E. Gerber
- , Laura Q. Chow
- , Rosalyn A. Juergens
- , Frances A. Shepherd
- , Scott A. Laurie
- , William J. Geese
- , Shruti Agrawal
- , Tina C. Young
- , Xuemei Li
- , Scott J. Antonia
- Memorial Sloan-Kettering Cancer Center
- University of California at Los Angeles
- Yale University
- Johns Hopkins University
- Duke University
- University of Texas Southwestern Medical Center
- University of Washington
- McMaster University
- University of Toronto
- University of Ottawa
- Bristol-Myers Squibb
- University of South Florida
Research output: Contribution to journal › Article › peer-review
911
Scopus
citations